Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Til Schlotter

ETH Researcher, Co-founder & CEO

UNOMR AG

Zurich, Switzerland

2 profile visits

Revolutionizing Precision Medicine with Nanopore-Based Protein Sequencing

My organisation

UNOMR AG

UNOMR AG

SME

Zurich, Switzerland

UNOMR, a techBio startup from ETH Zurich, is pioneering single-molecule protein sequencing through their innovative interface nanopore sensor, currently with a focus on site-specific protein glycosylation. Adressing a US$ 60B market, their patented solution has far-reaching applications across healthcare, pharmaceutical development, and food science, offering a powerful new tool for therapeutic discovery and medical food product innovation. Driven by the vision of bringing advanced proteomics directly to the patient, UNOMR aims to catalyze the next breakthrough in precision medicine by making sophisticated protein analysis accessible.
Read more

About me

Til Schlotter earned his BSc and MSc in Engineering from ETH Zurich and completed his diploma thesis at the University of British Columbia. He later completed his PhD at ETH Zurich, where he pioneered the development of the interface nanopore technology that powers UNOMR’s innovative approach to proteomics and precision medicine.

Before founding UNOMR AG, Til gained experience in strategy and business development as a management consultant at Deloitte and ETH Juniors.

As CEO, he leads application development, customer engagement, and fundraising to bring UNOMR’s platform to market. Under his leadership, the company has secured support from programs such as Venture Kick and InnoBooster, advancing its mission to make high-resolution protein modification analysis widely accessible across healthcare, pharmaceutical R&D, and food science.

Social media